Rx for Biotech

Listen to Francesca Cook, VP of Market Access at Regenexbio, as she provides an overview of the program and what to expect at the American Society of Gene and Cell Therapy’s upcoming Policy Summit being held in Washington, DC, on September 18th and 19th, 2023.

Check out the full program and register online at https://asgct.org/advocacy/policy-summit/agenda

In this podcast episode, our guest is Mark McDonough, CEO of ChromaCode.

ChromaCode is an innovator in genomics with a multiplexing platform that is driving integration from laboratories to physicians to patients, connecting them to the right treatment through its proven HDPCR™ multiplexing platform. This adaptable technology expands the accessibility of diagnostic applications to patient communities with a cost effective and scalable dPCR-based solution compatible with existing instrumentation and using standard workflows

In this podcast episode, our guest is Dr. Fahar Merchant, President and CEO of Medicenna Therapeutics. Medicenna is a clinical stage immunotherapy company that engineers novel, powerful and proprietary interleukins leveraging their Superkine Platform to modulate, fine-tune or amplify the immune system to tackle the most challenging diseases, including a broad range of cancers.

In this podcast episode, Tomasz George, Chief Scientific Officer at Virax Biolabs, shares how the company's ViraxImmune™ technology platform will empower patients to take control of their health and make informed decisions on how to respond to current and future viral threats. The company hopes their ViraxImmune™ platform will shift the way individuals are able to manage aspects of their immune health.

In this podcast episode, Dr. Michael Alonso, VP of Immunology and Pharmacology at Bolt Biotherapeutics, discusses how the company is developing cancer therapies that engage the innate immune system to generate robust anti-tumor responses.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases including mitochondrial diseases with significant unmet medical needs. In this podcast episode, we speak with Gregory Flesher, President and CEO of Reneo to learn more about mavodelpar, the company's lead asset, which is being developed in two rare diseases, primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).

In this podcast episode, Cyclacel CEO and President, Spiro Rombotis, shares how the company, is exploiting deeper understanding of molecular oncology to develop novel precision medicines based on cell cycle, transcriptional regulation, and mitosis biology.

Chris Leidli reviews scientific and clinical highlights from the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting with guest, Benjamin McLeod, MBIOT.

In this podcast episode, Dr. Philip Kantoff, the CEO, CMO, and Co-Founder of Convergent Therapeutics reviews the company's efforts to develop next-generation radiopharmaceuticals for the treatment of cancer.

FibroBiologics is the leading biotech company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. In this podcast episode, the Founder and CEO, Pete O'Heeron discusses the promise of fibroblast cell therapy to treat diseases such as multiple sclerosis, degenerative disk disease and more.